Key Takeaways
- Researchers at Brown University developed a genetically modified C. elegans nematode model to study alternating hemiplegia of childhood (AHC).
- The model allows rapid screening of potential drug treatments for AHC, a currently untreatable genetic disorder.
- Funding was provided by several foundations, highlighting the urgency for effective treatments as AHC symptoms worsen with age.
A new study from Brown University introduces a genetically modified model of C. elegans nematodes, aimed at advancing treatment for alternating hemiplegia of childhood (AHC), a rare genetic disorder causing paralysis in young patients. Developed under the guidance of neuroscientist Anne Hart, this model represents a cost-effective method to evaluate possible drug therapies for a condition that has no definitive cure.
“Humans and C. elegans share many genetic traits, including those related to AHC,” explained Hart, a professor of neuroscience affiliated with the Carney Institute for Brain Science. Due to their small size and ease of maintenance, C. elegans serve as an ideal platform for swift drug screening aimed at alleviating AHC symptoms.
A recent paper published in the journal Disease Models and Mechanisms, led by Ph.D. student Diana Wall, outlines the varying symptoms associated with AHC. Manifestations can include full-body paralysis, severe muscle spasms, seizures, and autonomic dysfunction, with episodes ranging in duration from minutes to days. AHC is primarily caused by mutations in the ATP1A3 gene, which produces an enzyme crucial for proper nerve and muscle function. The study indicated that these mutations disrupt the enzyme’s activity, resulting in diverse symptoms among patients.
The research team is focused on creating a robust framework for testing drug treatments, a transformative opportunity for children and families impacted by this disorder. Nina Frost, founder of the nonprofit RARE Hope, noted the progress being made. “We’re evolving from limited treatment options to potentially screening thousands of compounds across three variants of AHC that cover nearly half of all cases,” she stated. Frost’s personal connection to the disease, with her daughter Annabel suffering from AHC, adds urgency to this research endeavor.
“For a parent like me, watching my 10-year-old’s condition worsen, this research offers real hope,” Frost expressed.
Wall, who has engaged with families at AHC symposiums, emphasized the significance of addressing an under-researched condition like AHC. “Interacting with the children affected by AHC, knowing that my work could make a real difference, is immensely rewarding,” she said.
The study’s funding came from various organizations, including the National Institutes of Health and foundations dedicated to supporting AHC research, underscoring the critical need for effective treatments.
This novel nematode model could pave the way for groundbreaking developments in the treatment of AHC, bringing renewed hope to families grappling with this challenging disorder.
The content above is a summary. For more details, see the source article.